Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | RORC | P51449 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21859073 | 0.83 | LMNA (0.43) | USP2GLAKDM4EMEN1KMT2A | |
| SCHEMBL24037263 | 0.82 | TSHR (0.40) | USP2GLAKDM4EMEN1KMT2A | |
| SCHEMBL24037264 | 0.80 | KDM4E (0.50) | KDM4EMEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL8195632 | 0.78 | MAPT (0.46) | USP2GLAKDM4EMEN1KMT2A | |
| SCHEMBL12685429 | 0.78 | USP2 (0.46) | USP2GLAKDM4EMEN1KMT2A | |
| SCHEMBL24037434 | 0.78 | USP2 (0.46) | USP2GLAKDM4EMEN1KMT2A | |
| SCHEMBL8203304 | 0.77 | USP2 (0.58) | USP2GLAKDM4EMEN1KMT2A | |
| SCHEMBL21859026 | 0.76 | LMNA (0.56) | KDM4EMEN1KMT2AMAPTLMNA | |
| SCHEMBL24037529 | 0.75 | HTR2C (0.42) | KDM4EMEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL24037531 | 0.75 | HTR2C (0.42) | KDM4EMEN1KMT2ALMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210355124-A1 | Cyclic compounds as receptor modulating therapeutics and methods and uses thereof | BIONOMICS LIMITED (AU) | 2021-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210355124-A1 | Cyclic compounds as receptor modulating therapeutics and methods and uses thereof | CHRNA7, CHRNA1, CHRNA5 | USP2 3711/4885GLA 1136/4885KDM4E 3556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.